This supplement (the "Supplement", which definition shall also include all information incorporated by reference herein) to the base prospectus dated 4th August, 2020 (the "Prospectus", which definition includes the Prospectus as supplemented, amended or updated from time to time and includes all information incorporated by reference therein) constitutes a supplementary prospectus for the purposes of Section 87G of the Financial Services and Markets Act 2000, as amended (the "FSMA") and is prepared in connection with the £20,000,000,000 Euro Medium Term Note Programme (the "Programme") of GlaxoSmithKline plc ("GSK plc"), GlaxoSmithKline Capital plc ("GSK Capital plc") and GSK Capital K.K. ("GSK Capital K.K.", and, together with GSK plc and GSK Capital plc, the "Issuers" and each an "Issuer"). The payment of all amounts owing in respect of Notes issued under the Programme by GSK Capital plc and GSK Capital K.K. will be unconditionally and irrevocably guaranteed by GSK plc (the "Guarantor").

Terms defined in the Prospectus have the same meaning when used in this Supplement.

This Supplement has been approved by the United Kingdom's Financial Conduct Authority (the "FCA"), in its capacity as competent authority for the purposes of Regulation (EU) 2017/1129 (the "Prospectus Regulation"), as a supplement to the Prospectus. The Prospectus comprises a base prospectus for the purposes of Article 8 of the Prospectus Regulation.

Each Issuer and the Guarantor accepts responsibility for the information contained in this Supplement. To the best of the knowledge and belief of each Issuer and the Guarantor the information contained in this Supplement is in accordance with the facts and this Supplement does not omit anything likely to affect the import of such information. No other person has authorised or is responsible for the whole or any part of this Supplement or has any liability with respect to it.

This Supplement is supplemental to, updates, must be read in conjunction with, and forms part of, the Prospectus and any other supplements to the Prospectus issued by the Issuers and the Guarantor.

Other than in relation to the documents which are deemed to be incorporated by reference, the information on the websites to which this Supplement refers does not form part of this Supplement and has not been scrutinised or approved by the FCA.

The purpose of this Supplement is to incorporate by reference into the Prospectus (a) the Group's Results Announcement for the third quarter 2020 (as defined below) and (b) the press release, dated 3rd
November, 2020, entitled "GSK sets new environmental goals of net zero impact on climate and net positive impact on nature by 2030".

**Documents Incorporated by Reference**

The following documents which have been previously published, or are published simultaneously with this Supplement and have been filed with the FCA shall be deemed to be incorporated in, and to form part of, this Supplement and, by virtue of this Supplement, shall be deemed to be incorporated in, and to form part of, the Prospectus:

1. the press release dated 28th October, 2020 (which can be accessed from the following hyperlink: [https://www.gsk.com/media/6189/q3-2020-results-announcement.pdf](https://www.gsk.com/media/6189/q3-2020-results-announcement.pdf)) containing the unaudited interim condensed financial information of the Group for the three months ended 30th September, 2020 (the "Group's Results Announcement for the third quarter 2020"); and


Any documents themselves incorporated by reference in the Group's Results Announcement for the third quarter 2020 shall not form part of this Supplement.

Copies of this Supplement and the Group's Results Announcement for the third quarter 2020, incorporated by reference herein have been filed with Morningstar plc (appointed by the FCA to act as the National Storage Mechanism), and are available for viewing at [https://data.fca.org.uk/#/nsm/nationalstoragemechanism](https://data.fca.org.uk/#/nsm/nationalstoragemechanism).

**Additional Information**

The three paragraphs under the subheading "Significant or Material Change" on page 91 of the Prospectus shall be deemed to be deleted in its entirety and replaced with the following text:

"There has been no significant change in the financial performance and the financial position of GSK plc and/or the Group since 30th September, 2020 and there has been no material adverse change in the prospects of GSK plc and/or the Group since 31st December, 2019.

There has been no significant change in the financial performance and the financial position of GSK Capital plc since 30th June, 2020 and there has been no material adverse change in the prospects of GSK Capital plc since 31st December, 2019.

There has been no significant change in the financial performance and the financial position of GSK Capital K.K. since 31st December, 2019 and there has been no material adverse change in the prospects of GSK Capital K.K. since 31st December, 2019."

The two paragraphs under the subheading "Litigation" on page 91 of the Prospectus shall be deemed to be deleted in their entirety and replaced with the following text:

"References in this section "General Information – Litigation" to the "Financial Statements" mean the financial statements in the Group's Annual Report 2019.

Save as disclosed in Note 14, "Taxation", to the Financial Statements set out on pages 189 to 191 of the Group's Annual Report 2019, Note 46, "Legal proceedings", to the Financial Statements set out on pages 247 to 251 of the Group's Annual Report 2019 and "Legal matters" and "Taxation" each set out on pages 58 and 22 respectively of the Group's Results Announcement for the third quarter 2020 (which are incorporated by reference), there are no governmental, legal or arbitration proceedings, including any
which are pending or threatened, of which the Issuers or the Guarantor are aware, which may have, or have had during the 12 months prior to the date of this Prospectus or in the recent past, a significant effect on the financial position or profitability of any of GSK plc and/or GSK Capital plc and/or GSK Capital K.K. and/or the Group. As at 30th September 2020, the Group had £0.3 billion (31st December, 2019 £0.2 billion) of provisions for legal and other disputes and other matters, including amounts relating to legal and administrative proceedings, principally product liability, intellectual property, tax, anti-trust and governmental investigations as well as related private litigation but excluding tax matters disclosed in Note 14, "Taxation", to the Financial Statements set out on pages 189 to 191 of the Group's Annual Report 2019 and in "Taxation" set out on page 22 of the Group's Results Announcement for the third quarter 2020. Legal provisions are disclosed in detail in Note 31, "Other provisions", to the Financial Statements set out on pages 214 to 215 of the Group's Annual Report 2019.

To the extent there is any inconsistency between (a) any statement in this Supplement or any statement incorporated by reference into the Prospectus by this Supplement and (b) any other statement in, or incorporated by reference in, the Prospectus prior to the date of this Supplement, the statements in (a) above will prevail.

Save as disclosed in this Supplement and the Prospectus, neither the Issuers nor the Guarantor is aware of any other significant new factor, material mistake or material inaccuracy relating to information included in the Prospectus which is capable of affecting an informed assessment by investors of Notes issued under the Programme since the publication of the Prospectus.